Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Business
Weight Loss Medications Trigger 'Major Impact' on Tailoring, Says Savile Row Executive
S
Shotlee
Health & Wellness Team
2 min read
Preparing your Shotlee experience
A Savile Row executive reports that the increasing use of weight loss medications is causing substantial changes in the tailoring business. Rapid weight loss among customers necessitates significant alterations or complete remakes of suits. This trend is particularly noticeable among male clients in their 40s and 50s.
The tailoring sector is experiencing "massive repercussions" due to the increased use of weight loss medications, according to a Savile Row executive.
Sean Dixon, the co-founder of tailor Richard James, stated that their cutters are needing to make considerable adjustments or completely remake suits due to the rapid weight loss experienced by some clients. The trend is particularly evident among male customers, many of whom are in their 40s and 50s.
He told the PA news agency, that male clients are using these drugs and losing a considerable amount of weight, likely for health reasons, which is a positive development. The weight loss isn't minor; it's substantial enough to necessitate a completely new tailored wardrobe.
Mr. Dixon clarified that bespoke commissions can take up to three months. Therefore, people's measurements can drastically change between the initial and final fittings.
"That has massive repercussions," he noted, emphasizing that "bespoke tailoring is made to fit precisely."
People are losing as much as 25 kilograms in a relatively short period, which fundamentally alters the tailoring requirements. Suits can't simply be altered; they often need to be completely remade from scratch.
The business is actively exploring solutions to address this issue without increasing costs or compromising customer sensitivity. Health tracking apps like Shotlee can help monitor such changes, providing valuable data for tailors to work with.
Recent estimates indicate that approximately 1.5 million people in the UK are using GLP-1s, the scientific name for weight loss injections, which function by curbing food cravings.
A recent poll by anti-obesity drugs provider CheqUp revealed that over 10% of Britons anticipate hosting someone taking GLP-1 medication during the Christmas season.
Half of those surveyed indicated they would reconsider gifting clothing to friends and family due to sensitivities surrounding weight loss.
Among GLP-1 users, over half reported that they would consume smaller portions and indulge in fewer treats during the festive season.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from Yahoo
View Original Article
China's pharmaceutical industry is rapidly ascending on the global stage, fueled by innovation and strategic alliances with Western companies. This rise presents both opportunities and challenges as China aims to become a major player in drug discovery and development.
Pfizer has successfully acquired Metsera, a company specializing in obesity drug development, for $10 billion, prevailing over Novo Nordisk in a competitive bidding process. This acquisition marks Pfizer's entry into the expanding obesity drug market. Metsera's treatments are still several years from regulatory approval.
Novo Nordisk is escalating its efforts to acquire Metsera, raising its offer to $10 billion to outbid Pfizer. This move comes as both pharmaceutical giants aim to strengthen their positions in the lucrative obesity and diabetes treatment markets. Pfizer has also adjusted its offer with more upfront cash.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨